發送短信 : Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

  _____      ___      _____    __   __   _____    
 / ____||   / _ \\   /  ___||  \ \\/ // |  __ \\  
/ //---`'  | / \ || | // __     \ ` //  | |  \ || 
\ \\___    | \_/ || | \\_\ ||    | ||   | |__/ || 
 \_____||   \___//   \____//     |_||   |_____//  
  `----`    `---`     `---`      `-`'    -----`